FNBT
UNCY icon

FineMark National Bank & Trust’s Unicycive Therapeutics UNCY Stock Holding History

FineMark National Bank & Trust’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,563
Closed -$9K – 420
2022
Q3 		$9K Hold
1,563
– – ﹤0.01% 385
2022
Q2 		$13K Buy
+1,563
New +$14.9K ﹤0.01% 414

Other funds holding UNCY

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tandem Capital Management Woodcliff Lake, New Jersey $200M AUM 25.01% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

FineMark National Bank & Trust's UNCY Position: Q4 2022 in Review

FineMark National Bank & Trust sold out of Unicycive Therapeutics (UNCY) in Q4 2022, closing a stake of 1,563 shares — an estimated $9K sold.

FineMark National Bank & Trust first reported a position in UNCY in Q2 2022 and held it in 2 quarters. The position peaked at $13K in Q2 2022. 9 funds tracked by Wall St. Rank hold UNCY as of Q4 2022.

  • FineMark National Bank & Trust reported no remaining Unicycive Therapeutics position as of Q4 2022 after selling out during the quarter.
  • FineMark National Bank & Trust sold 1,563 Unicycive Therapeutics shares in Q4 2022, an estimated $9K.
  • FineMark National Bank & Trust first reported a position in Unicycive Therapeutics in Q2 2022 and held it in 2 quarters.
  • FineMark National Bank & Trust's Unicycive Therapeutics position peaked at $13K in Q2 2022.
  • 9 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q4 2022.

Based on FineMark National Bank & Trust's 13F filing for Q4 2022, filed 9 Feb 2023.